Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Benton Intersects 22.0 m Grading 7.47% Copper Including 8.0 m Grading 11.93% Copper (click to learn more) Almonty Announces Intention to Relocate to the United States (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:TOVX)

Theriva(TM) Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

GlobeNewswire December 5, 2024

Theriva(TM) Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results

GlobeNewswire November 12, 2024

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

GlobeNewswire October 31, 2024

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

GlobeNewswire October 16, 2024

Theriva(TM) Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

GlobeNewswire October 3, 2024

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

GlobeNewswire September 26, 2024

Theriva(TM) Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

GlobeNewswire September 23, 2024

Theriva(TM) Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

GlobeNewswire September 16, 2024

Theriva Biologics Announces Reverse Stock Split

GlobeNewswire August 16, 2024
View More News ››

Opinion & Analysis (NYSEAM:TOVX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:TOVX)

TOVX.....Just tapped N.L.O.D

$1.51 How am i doing ?
Iseneschal - October 3, 2024

TOVX.....Dumpfest on the opening bell

Told ya ; )
Iseneschal - October 3, 2024

TOVX.....early a.m runner on NR...set up for P.O ; )

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of...
Iseneschal - October 3, 2024

Theriva Biologics, Inc. (TOVX): Advancing Oncology Pipeline

http://beyondspx.com/2024/08/03/theriva-biologics-inc-tovx-advancing-oncology-pipeline-with-promising-vcn-01-data/
MikeTester - August 3, 2024

TOVX..... Volume update at 11:10 p.s.t

490,000 shs have traded since 10:43
Iseneschal - June 28, 2023

TOVX.... This will be a screaming buy if...big if ....

it crosses the $1.06 resistance Me no position unless it does ....with volum e
Iseneschal - June 28, 2023
View more Bullboard ››

Coelacanth Energy Inc.

Coelacanth Energy Inc.

Coelacanth Energy Inc. is a Montney-focused oil and natural gas exploration and development company, with lands located in ...
View More »